ALSO NOTED: Map files for $86M IPO; NicOx halts trial; Geron increases stake in JV; and much more...

> Map Pharmaceuticals, which is developing new therapies for asthma and migraines, has filed for an $86.2 million IPO. Report

> France's NicOx announced that the NCI is halting a Phase I trial of NCX 4016 for colon cancer after tests regarding a related molecule demonstrated that it might harm DNA. NicOx says it plans more tests for the therapy and would delay a Phase II diabetes study until it had more information regarding NCX 4015. Report

> Geron has increased its stake in a joint venture entity formed with the Biotechnology Research Corporation, TA Therapeutics Limited (TAT), from 50 percent ownership to 75 percent ownership. Release

> Basilea Pharmaceutica earned a $9.8 million milestone with its submission of the superbug antibiotic ceftobiprole to the European Medicines Agency for approval. Report

> Aptuit and Laurus Labs have created a new contract drug development company, Aptuit Laurus. Report

And Finally… Economic development officials in San Francisco have been touting the rapid growth of the city's biotech sector. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.